If this message displays incorrectly, please view the web page

OCTOBER 24, 2016

Research Extras

Zika viru
Aftab Ansari (pictured with Kristina Ortiz and Dawn Little) collaborated with Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, on a study that has controlled SIV in primates at Yerkes Research Center almost two years after drug therapy was withdrawn.

Sustained control of SIV achieved through antibody supplement to drug therapy
Scientists have achieved sustained control of SIV infection (the non-human primate counterpart of HIV) in rhesus macaques by supplementing antiretroviral drugs with an antibody during and after drug treatment. When drug treatment was stopped, the virus did not re-emerge and cause disease. This was the first consistent demonstration of post-treatment immune control in monkeys infected with this variety of SIV, without previous vaccination. While virus is still present in the antibody-treated monkeys, it has stayed below the limit of detectability in their blood. A pilot clinical trial testing the antibody's effect on HIV in people has begun at NIAID.

Liver Disease
ASBT inhibitors interfere with bile acid recycling in the intestine and can improve liver function and reduce insulin resistance in mice. Human clinical trials are on the horizon.
Bile acid uptake inhibitors may prevent nonalcoholic fatty liver disease
Drugs called ASBT inhibitors were successful in preventing nonalcoholic fatty liver disease in laboratory mice, suggesting they could be a useful clinical strategy for people. Nonalcoholic steatohepatitis (NASH) is an increasingly common liver disease linked to diet and obesity. It confers an elevated risk of type II diabetes and heart disease and can progress to cirrhosis. Read more...

Flu Virus
A vaccine against many varieties of the common cold will be developed by Emory startup company Meissa Vaccines, Inc.
Vaccine may be achievable against many cold viruses at once
The existence of more than 100 varieties of rhinovirus circulating globally has seemed like a daunting challenge for vaccine researchers. But by mixing together dozens of different inactivated cold viruses, researchers have developed a vaccine using neutralizing antibodies that can prevent infection in the laboratory and will soon be tested in human clinical trials. Read more...

Research Funding
The Woodruff Health Sciences Center received $540 million, or 94 percent of Emory research funding.
Annual Emory research funding tops $574.6 million
Federal agencies awarded Emory researchers $389.7 million in FY16, including $333 million from the NIH, as Emory researchers attracted a total of $574.6 million, topping half a billion dollars for the seventh straight year. Funding was primarily health related, including for infectious diseases, Alzheimer's, environmental health, cardiology, nanotechnology, and immunotherapy. Read more...

Editor, Holly Korschun, Executive Director of Research Communications
Managing Editor, David S. Stephens, MD, Vice President for Research